BACKGROUND: Pneumococcal nasopharyngeal colonization is a prerequisite to developing pneumococcal disease. We investigated the dynamics of pneumococcal colonization in perinatal HIV-unexposed and HIV-exposed children and their mothers and risk factors associated with new serotypes acquisition. METHODS: Two hundred forty-three mother-child pairs (120 HIV-infected, 123 HIV-uninfected mothers) were studied at 4.4, 7.2, 9.4, 12.3 and 16.0 months of the child's age. Demographic data, nasopharyngeal swabs, as well as oropharyngeal swabs, from mothers were collected for pneumococcal conventional culture and serotyping by the Quellung method. RESULTS: The rate of new serotype acquisition during the 16 months did not differ between HIV-exposed (49.1%) and HIV-unexposed (52.0%) children, or between HIV-infected (18.9%) and HIV-uninfected (19.5%) mothers. Serotypes included in the 7-valent pneumococcal conjugate vaccine (PCV7) were acquired more often by HIV-infected (10.0%) compared with HIV-uninfected mothers (6.4%; P = 0.03). On multivariate analysis, day-care attendance (adjusted odds ratio [AOR], = 1.80, P = 0.02) and maternal pneumococcal colonization (AOR = 1.54, P = 0.01) were positively associated with pneumococcal acquisition in the child, whereas breast-feeding had a protective effect on PCV7-serotype acquisition in HIV-uninfected children. New acquisition of PCV7 and PCV13 serotypes in the mother was positively associated with colonization in the child (AOR = 2.01, P = 0.006 and AOR = 2.04, P = 0.002, respectively). CONCLUSIONS: There is an association of acquisition of PCV7 and PCV13 serotypes between young children and their mothers. The higher prevalence of PCV7 serotype in HIV-infected mothers suggests that they may be a reservoir for transmission of these serotypes, which could delay indirect effects of PCV in settings with a high HIV burden.
BACKGROUND:Pneumococcal nasopharyngeal colonization is a prerequisite to developing pneumococcal disease. We investigated the dynamics of pneumococcal colonization in perinatal HIV-unexposed and HIV-exposed children and their mothers and risk factors associated with new serotypes acquisition. METHODS: Two hundred forty-three mother-child pairs (120 HIV-infected, 123 HIV-uninfected mothers) were studied at 4.4, 7.2, 9.4, 12.3 and 16.0 months of the child's age. Demographic data, nasopharyngeal swabs, as well as oropharyngeal swabs, from mothers were collected for pneumococcal conventional culture and serotyping by the Quellung method. RESULTS: The rate of new serotype acquisition during the 16 months did not differ between HIV-exposed (49.1%) and HIV-unexposed (52.0%) children, or between HIV-infected (18.9%) and HIV-uninfected (19.5%) mothers. Serotypes included in the 7-valent pneumococcal conjugate vaccine (PCV7) were acquired more often by HIV-infected (10.0%) compared with HIV-uninfected mothers (6.4%; P = 0.03). On multivariate analysis, day-care attendance (adjusted odds ratio [AOR], = 1.80, P = 0.02) and maternal pneumococcal colonization (AOR = 1.54, P = 0.01) were positively associated with pneumococcal acquisition in the child, whereas breast-feeding had a protective effect on PCV7-serotype acquisition in HIV-uninfectedchildren. New acquisition of PCV7 and PCV13 serotypes in the mother was positively associated with colonization in the child (AOR = 2.01, P = 0.006 and AOR = 2.04, P = 0.002, respectively). CONCLUSIONS: There is an association of acquisition of PCV7 and PCV13 serotypes between young children and their mothers. The higher prevalence of PCV7 serotype in HIV-infected mothers suggests that they may be a reservoir for transmission of these serotypes, which could delay indirect effects of PCV in settings with a high HIV burden.
Authors: Louise K Francois Watkins; Jennifer L Milucky; Lesley McGee; Florence Siné St-Surin; Pengbo Liu; Theresa Tran; Sopio Chochua; Gerard Joseph; Nong Shang; Stanley Juin; Patrick Dely; Roopal Patel; Chris A Van Beneden Journal: J Infect Dis Date: 2021-09-01 Impact factor: 7.759
Authors: Ellen Heinsbroek; Terence Tafatatha; Christina Chisambo; Amos Phiri; Oddie Mwiba; Bagrey Ngwira; Amelia C Crampin; Jonathan M Read; Neil French Journal: Am J Epidemiol Date: 2015-12-01 Impact factor: 4.897
Authors: Ann Lindstrand; Joan Kalyango; Tobias Alfvén; Jessica Darenberg; Daniel Kadobera; Freddie Bwanga; Stefan Peterson; Birgitta Henriques-Normark; Karin Källander Journal: PLoS One Date: 2016-11-09 Impact factor: 3.240
Authors: Courtney P Olwagen; Peter V Adrian; Marta C Nunes; Michelle J Groome; Mark F Cotton; Avy Violari; Shabir A Madhi Journal: mSphere Date: 2017-11-08 Impact factor: 4.389
Authors: Tinevimbo Shiri; Marta C Nunes; Peter V Adrian; Nadia Van Niekerk; Keith P Klugman; Shabir A Madhi Journal: BMC Infect Dis Date: 2013-10-17 Impact factor: 3.090
Authors: Laura M Conklin; Godfrey Bigogo; Geofrey Jagero; Lee Hampton; Muthoni Junghae; Maria da Gloria Carvalho; Fabiana Pimenta; Bernard Beall; Thomas Taylor; Brian Plikaytis; Kayla F Laserson; John Vulule; Chris Van Beneden; Cynthia G Whitney; Robert F Breiman; Daniel R Feikin Journal: BMC Infect Dis Date: 2016-01-16 Impact factor: 3.090
Authors: Todd D Swarthout; Ana Ibarz-Pavon; Gift Kawalazira; George Sinjani; James Chirombo; Andrea Gori; Peter Chalusa; Farouck Bonomali; Roseline Nyirenda; Edwin Bulla; Comfort Brown; Jacquline Msefula; Marjory Banda; Jean Kachala; Charles Mwansambo; Marc Yr Henrion; Stephen B Gordon; Neil French; Robert S Heyderman Journal: BMJ Open Date: 2021-06-17 Impact factor: 2.692